A growing understanding of how “reproductive” hormones sculpt the brain could transform the management of neurological ...

Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, often emerging in early adulthood and representing a leading cause of neurological disability in young ...

A new study has identified the protein hnRNP A1 as a key player in the production and maintenance of myelin, the fatty sheath ...

Research published in the Journal of Neurochemistry has detailed the role of a protein, hnRNP A1, in the formation and ...

Research published in the Journal of Neurochemistry has detailed the role of a protein, hnRNP A1, in the formation and ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

About multiple sclerosis Multiple sclerosis is a chronic, immune-mediated disease of the central nervous system that may result ... causes of neurological diseases and potentially transform ...

and B cells in both the periphery and central nervous system. There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis. In a phase 3, double-blind, placebo ...